Fluticasone and budesonide nanosuspensions for pulmonary delivery: Preparation, characterization, and pharmacokinetic studies

Journal of Pharmaceutical Sciences

Volumn 97, Issue 11, 2008, Pages 4869-4878

  Yang, Jerry Z ^a   Young, Anthony L ^a   Chiang, Po Chang ^a   Thurston, Archie ^a   Pretzer, Denise K ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Milling; Nanoparticles; Particle size; Physical characterization; Pulmonary delivery absorption; Pulmonary drug delivery

Indexed keywords

BUDESONIDE; FLUTICASONE PROPIONATE;

ANIMAL EXPERIMENT; ARTICLE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG FORMULATION; DRUG POTENCY; DRUG STABILITY; MALE; NANOSUSPENSION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT; SUSPENSION;

EID: 55749114027     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21380     Document Type: Article

References (24)

1. Borgstrom L. 2001. The importance of the device in asthma therapy. Respir Med 95:S26-S29.
2. Courrier HM, Butz N, Vandamme TF. 2002. Pulmonary drug delivery systems: Recent developments and prospects. Crit Rev Ther Drug Carrier Syst 19:425-498.
3. Raeburn D, Underwood SL, Villamil ME. 1992. Techniques for drug delivery to the airways, and the assessment of lung function in animal models. J Pharmacol Toxicol Methods 27:143-159.
4. Suarez S, Hickey AJ. 2000. Drug properties affecting aerosol behavior. Respir Care 45:652-666.
5. Forbes B, Hashmi N, Martin GP, Lansley AB. 2000. Formulation of inhaled medicines: Effect of delivery vehicle on immortalized epithelial cells. J Aerosol Med 13:281-288.
6. Labiris NR, Dolovich MB. 2003. Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 56:600-612.
7. Grossman J. 1994. The evolution of inhaler technology. J Asthma 31:55-64.
8. Sakagami M. 2006. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 58:1030-1060.
9. Liao X, Wiedmann TS. 2003. Solubilization of cationic drugs in lung surfactant. Pharm Res 20:1858-1863.
10. Berry J, Kline LC, Sherwood JK, Chaudhry S, Obenauer-Kutner L, Hart JL, Sequeira J. 2004. Influence of the size of micronized active pharmaceutical ingredient on the aerodynamic particle size and stability of a metered dose inhaler. Drug Dev Ind Pharm 30:705-714.
11. Leong BK, Coombs JK, Sabaitis CP, Rop DA, Aaron CS. 1998. Quantitative morphometric analysis of pulmonary deposition of aerosol particles inhaled via intratracheal nebulization, intratracheal instillation or nose-only inhalation in rats. J Appl Toxicol 18:149-160.
12. Snipes MB, Chavez GT, Muggenburg BA. 1984. Disposition of 3-, 7-, and 13-microns microspheres instilled into lungs of dogs. Environ Res 33:333-342.
13. Atkins PJ. 2005. Dry powder inhalers: An overview. Respir Care 50:1304-1312, discussion 1312.
14. Telko MJ, Hickey AJ. 2005. Dry powder inhaler formulation. Respir Care 50:1209-1227.
15. Buckton G. 1997. Characterisation of small changes in the physical properties of powders of significance for dry powder inhaler formulations. Adv Drug Deliv Rev 26:17-27.
16. Merisko-Liversidge E, Liversidge GG, Cooper ER. 2003. Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 18:113-120.
17. Muller RH, Jacobs C, Kayser O. 2001. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 47:3-19.
18. Jacobs C, Muller RH. 2002. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res 19:189-194.
19. Szefler SJ, Eigen H. 2002. Budesonide inhalation suspension: A nebulized corticosteroid for persistent asthma. J Allergy Clin Immunol 109:730-742.
20. Rogueda P. 2005. Novel hydrofluoroalkane suspension formulations for respiratory drug delivery. Expert Opin Drug Deliv 2:625-638.
21. Kraft WK, Steiger B, Beussink D, Quiring JN, Fitzgerald N, Greenberg HE, Waldman SA. 2004. The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J Clin Pharmacol 44:67-72.
22. Rasenack N, Muller BW. 2004. Micron-size drug particles: Common and novel micronization techniques. Pharm Dev Technol 9:1-13.
23. Kondo N, Iwao T, Masuda H, Yamanouchi K, Ishihara Y, Yamada N, Haga T, Ogawa Y, Yokoyama K. 1993. Improved oral absorption of a poorly water-soluble drug, HO-221, by wet-bead milling producing particles in submicron region. Chem Pharm Bull (Tokyo) 41:737-740.
24. Haskell RJ. 1998. Characterization of submicron systems via optical methods. J Pharm Sci 87:125-129.